BioStock: International specialist congress and upcoming milestones for Chordate Medical
Chordate Medical has once again received the opportunity to present the company’s migraine treatment K.O.S at a scientific congress. This time at the International Headache Congress in Seoul, Korea, on September 14-17. In addition, the investigators in the PM007 study have submitted a manuscript for a scientific article, which CEO Anders Weilandt elaborates on.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se